摘要
目的探讨分析达格列净联合司美格鲁肽对2型糖尿病(type 2 diabetes mellitus,T2DM)合并代谢相关脂肪性肝病(metabolic related fatty liver disease,MAFLD)患者的糖脂代谢、肝功能和肝纤维化指标的影响。方法选取2021年7月—2022年12月徐州市贾汪区人民医院收治的120例T2DM合并MAFLD患者为研究对象,采用双盲法分为单一组和联合组,每组60例。单一组给予达格列净治疗,联合组给予达格列净和司美格鲁肽治疗。对比两组患者用药前后糖脂代谢指标、肝功能指标及肝纤维化指标,并观察用药后的不良反应发生情况。结果用药后,联合组患者的糖脂代谢指标均优于单一组,肝功能指标低于单一组,肝纤维化各项指标均低于单一组,差异有统计学意义(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论达格列净联合司美格鲁肽应用可有效帮助T2DM合并MAFLD患者控制血糖水平,改善肝功能损害情况和肝纤维化进展程度,且安全性较高。
Objective To investigate the effects of dapagliflozin combined with semaglutide on glycolipid metabolism,liver function and liver fibrosis in patients with type 2 diabetes mellitus(T2DM)combined metabolic related fatty liver disease(MAFLD).Methods A total of 120 T2DM patients with MAFLD admitted to Jiawang District People's Hospital of Xuzhou City from July 2021 to December 2022 were selected as research subjects and divided into single group and combined group by double-blind method,with 60 cases in each group.The single group was treated with dagaglizin,and the combination group was treated with dagaglizin and semaglutide.The indexes of glucose and lipid metabolism,liver function and liver fibrosis before and after medication were compared between the two groups,and the occurrence of adverse reactions after medication was observed.Results After medication,the glucose and lipid metabolism indexes of combined group were better than that of single group,liver function indexes were lower than that of single group,and liver fibrosis indexes were lower than that of single group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of dapagliflozin combined with semaglutide can effectively help T2DM patients with MAFLD control blood glucose level,improve liver function impairment and liver fibrosis progression,with high safety.
作者
代闪
王辰
DAI Shan;WANG Chen(Department of Endocrinology,Jiawang District People's Hospital,Xuzhou,Jiangsu Province,221000 China)
出处
《糖尿病新世界》
2023年第18期25-29,共5页
Diabetes New World Magazine
关键词
达格列净
司美格鲁肽
2型糖尿病
代谢相关脂肪性肝病
糖脂代谢
肝功能
Dapagliflozin
Semaglutide
Type 2 diabetes
Metabolically related fatty liver disease
Glycolipid metabolism
Liver function
